Go to podcast
by Oncolgy Times & Audio Medica
Oncology Times Broadcast News

Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer

Description

Oncology Times Broadcast News: Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer For adjuvant treatment of stage II and stage III colorectal cancer the vascular endothelial growth factor (VEGF) receptor inhibitor, bevacizumab, gave no benefit in disease-free survival after a median follow up of three years when added to standard oxaliplatin-based chemotherapy in the NSABP C-O8 phase III study reported at the 2009 ASCO meeting held in Orlando, Florida . Lead author Dr Norman Wolmark MD Chair of the National Surgical Adjuvant Breast and Bowel Project, and Chair of the Department of Oncology at Allegheny General Hospital in Pittsburgh, said in an interview with Peter Goodwin: "These data do not support using bevacizumab in the adjuvant setting."

Details

Episode

by Oncolgy Times & Audio Medica